FDA approves 1st 2-drug HIV treatment
Ella Jeffries / beckershospitalreview - The FDA has approved Merck’s once-daily, two-drug regimen for adults with virologically suppressed HIV-1. The treatment combines 100 mg doravirine and 0.25 mg islatravir and is indicated for patients with no history of virologic treatment failure and no k…
AI Summary: The FDA has approved Merck’s once‑daily two‑drug antiretroviral regimen, marking a notable market entrant poised to compete with established single‑pill therapies. Regulators cleared the novel combination on efficacy and safety data, setting up potential shifts in prescribing, pricing and competition — and giving Gilead something new to grumble about.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
FDA approves Travere's Filspari for rare kidney disease FSGS / 6 wks
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 13 days
Antiviral ensitrelvir dramatically cuts household COVID transmission risk / 15 days
Denali drug receives accelerated approval for rare CNS indication / 2 months
FDA again rejects Aldeyra’s dry‑eye drug for weak evidence / 2 months
Moderna reaches multibillion-dollar settlement over mRNA patents / 2 months
Analysis finds anti-amyloid Alzheimer's drugs lack meaningful benefit / 6 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Avian Influenza, CDC, Venture Capital, None and look for the RSS link.
StackHealth Time Machine